Relay Therapeutics, Inc. (RLAY) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High cash burn • Strong liquidity • Negative profitability RLAY has strong liquidity and low leverage but is burning cash heavily—large R&D/opex drive deep operating and FCF losses and negative margins while invested assets and market valuation imply optimistic future optionality.
Price Behavior
Key Price Behavior Insights: • Fresh new high • Gap-up momentum • Extended above SMA Support Level: $9.35–$9.95 Resistance Level: $12.54 RLAY is in a short-term uptrend—making higher highs/lows and a fresh high at $12.54 after a large gap-up that leaves it ~23% above its last month SMA (~$10.17), boosting continuation odds but increasing mean-reversion risk toward the $9.35–$9.95 support band or the SMA.
Sentiment & News
Key News Insights: • Breakthrough designation • 11.1‑month PFS • Institutional buying Relay's positive ReDiscover Phase 1/2 efficacy and FDA Breakthrough designation for zovegalisib, plus planned presentations and notable institutional buying, have driven renewed investor interest and a stronger stock performance into April 2026.
AI Summary
RLAY has shifted into a concentrated, event-driven bet where zovegalisib's Phase 3 ReDiscover-2 readout (and upcoming vascular anomalies data) will likely determine near-term valuation, so investors should treat the stock as binary risk rather than a diversified platform play. Actionable triggers to monitor: confirmatory PFS/safety from ReDiscover-2, vascular anomalies signal, and any partner/non-dilutive financing to avoid urgent equity raises.
Description
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental methods to improve small-molecule discovery, initially concentrating on targeted oncology and genetic disease indications. Its clinical programs include an FGFR2 inhibitor (RLY-4008) in first-in-human testing, a mutant PI3Ka inhibitor program (RLY-2608), and an SHP2 inhibitor (RLY-1971) in Phase 1, and the company maintains research collaborations with D. E. Shaw Research for protein-motion modeling and with Genentech for development and commercialization of RLY-1971. Founded in 2015, Relay Therapeutics is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | RLAY | Relay Therapeutics, Inc. | Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events. | Active | +0.0% |